Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success

Drug Targets apoC-III To Lower Triglycerides

Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.

Anatomical model of pancreas on doctor table over background gastroenterologist consulting woman patient
A high dose of olezarsen eliminated risk of acute pancreatitis in FCS • Source: Shutterstock

Ionis Pharmaceuticals, Inc. took another step forward on its path to bringing its first wholly-owned drug to market without a partner on 26 September when it reported positive topline results from the Phase III BALANCE clinical trial of olezarsen in the treatment of familial chylomicronemia syndrome (FCS). The company plans to file for US and EU approvals during the first half of 2024 and, if granted priority review, expects US Food and Drug Administration approval before the end of next year and a launch soon after.

Key Takeaways

  • Ionis will file for US and EU approvals of olezarsen in FCS during the first half of 2024 based on positive results from the Phase III BALANCE study and expects FDA approval, assuming priority review due to a prior fast track designation, before the end of 2024.

The positive BALANCE readout also bodes well for olezarsen in the much larger indication of severe hypertriglyceridemia (SHTG), which encompasses...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D